These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25101565)

  • 41. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
    Strosberg JR; Weber JM; Choi J; Campos TL; Valone TL; Han G; Schell MJ; Kvols LK
    Ann Oncol; 2012 Sep; 23(9):2335-2341. PubMed ID: 22317769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reappraising antiangiogenic therapy for breast cancer.
    Kerbel RS
    Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors.
    Chen JL; Pan CK; Huang YS; Tsai CY; Wang CW; Lin YL; Kuo SH; Shieh MJ
    Cancer Immunol Immunother; 2021 Feb; 70(2):391-404. PubMed ID: 32761424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting immune suppressing myeloid-derived suppressor cells in oncology.
    Kao J; Ko EC; Eisenstein S; Sikora AG; Fu S; Chen SH
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):12-9. PubMed ID: 20304669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.
    MacIntyre J
    Clin J Oncol Nurs; 2007 Apr; 11(2):237-41. PubMed ID: 17573273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.
    Powles T; Chowdhury S; Bower M; Saunders N; Lim L; Shamash J; Sarwar N; Sadev A; Peters J; Green J; Boleti K; Augwal S
    Urol Int; 2011; 86(1):53-9. PubMed ID: 20975250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.
    Verma C; Eremin JM; Robins A; Bennett AJ; Cowley GP; El-Sheemy MA; Jibril JA; Eremin O
    J Transl Med; 2013 Jan; 11():16. PubMed ID: 23320561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia.
    Ahn A; Park CJ; Kim MS; Cho YU; Jang S; Bae MH; Lee JH; Lee JH; Koh KN; Im HJ
    Ann Lab Med; 2021 Sep; 41(5):479-484. PubMed ID: 33824236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
    Wang X; Zhang L; O'Neill A; Bahamon B; Alsop DC; Mier JW; Goldberg SN; Signoretti S; Atkins MB; Wood CG; Bhatt RS
    Br J Cancer; 2013 Feb; 108(2):319-26. PubMed ID: 23322198
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.
    Yoo C; Ryu YM; Kim SY; Kim J; Ock CY; Ryu MH; Kang YK
    Br J Cancer; 2019 Nov; 121(10):819-826. PubMed ID: 31607749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
    Molina AM; Jia X; Feldman DR; Hsieh JJ; Ginsberg MS; Velasco S; Patil S; Motzer RJ
    Clin Genitourin Cancer; 2013 Sep; 11(3):297-302. PubMed ID: 23707221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S; Demetri G; Sargent W; Raymond E
    Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
    Finke JH; Rini B; Ireland J; Rayman P; Richmond A; Golshayan A; Wood L; Elson P; Garcia J; Dreicer R; Bukowski R
    Clin Cancer Res; 2008 Oct; 14(20):6674-82. PubMed ID: 18927310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.